Medical Pharmacology: Chapter 18: Antiparkinson's Disease Drugs -- Module 8: Drug-Induced Parkinsonism, Special Populations, and Integrated Practice

Chapter 18: Antiparkinson's Disease Drugs — Module 8: Drug-Induced Parkinsonism, Special Populations, and Integrated Practice

1. A 59-year-old man with a ten-year history of schizoaffective disorder has been stable on olanzapine 15 mg nightly for three years. Over the past four months he has developed progressive bilateral bradykinesia, mild cogwheel rigidity, and a shuffling gait. His psychiatrist confirms the antipsychotic cannot be discontinued given the severity of his psychiatric history. DAT-SPECT shows normal dopamine transporter binding. Which pharmacological intervention is most appropriate to address his parkinsonism while maintaining psychiatric stability?

A) Add levodopa/carbidopa 25/100 mg three times daily to supplement dopaminergic tone at the partially blocked D2 receptors
B) Add trihexyphenidyl 2 mg twice daily to counterbalance the dopaminergic deficit through anticholinergic striatal rebalancing, accepting the cognitive adverse effect risk in this middle-aged patient
C) Switch olanzapine to quetiapine at an equivalent psychiatric dose, as quetiapine has substantially lower D2 receptor affinity at clinical doses and may allow partial motor recovery while maintaining antipsychotic efficacy
D) Add pramipexole 0.5 mg three times daily to provide direct dopamine agonist activity at the partially unblocked D3 receptors, bypassing the D2 blockade
E) Reduce the olanzapine dose by 50% and monitor for both motor improvement and psychiatric relapse, accepting reduced antipsychotic coverage as the only viable strategy

ANSWER: C

Rationale:

This question asked you to select the most appropriate pharmacological intervention for drug-induced parkinsonism in a patient whose antipsychotic cannot be discontinued. Option C is correct. The clinical picture — bilateral symmetric parkinsonism developing on a D2-blocking antipsychotic, confirmed by a normal DAT scan indicating structurally intact nigrostriatal neurons — is classic drug-induced parkinsonism from D2 receptor antagonism. When the causative antipsychotic cannot be discontinued, the established strategy is substitution with an antipsychotic that has substantially lower D2 receptor affinity. Quetiapine exerts its antipsychotic effects predominantly through mechanisms other than high-affinity D2 blockade and has very low striatal D2 occupancy at clinical psychiatric doses. This allows partial recovery of dopaminergic motor function while maintaining adequate control of psychotic symptoms. Clozapine is an alternative with even lower D2 affinity but requires mandatory blood count monitoring for agranulocytosis, making quetiapine a more straightforward first choice.

Option A: Option A is incorrect. Levodopa is pharmacologically ineffective in antipsychotic-induced DIP because the postsynaptic D2 receptor is occupied by olanzapine; increasing synaptic dopamine cannot act at a blocked receptor regardless of how much levodopa is provided.
Option B: Option B is incorrect. Trihexyphenidyl can provide modest symptomatic benefit in DIP through anticholinergic striatal rebalancing, but its cognitive adverse effects — confusion, memory impairment, and delirium risk — are a significant concern even in a 59-year-old, and it is not the preferred primary strategy when receptor substitution is feasible; switching to a lower-D2-affinity antipsychotic addresses the root pharmacological cause more directly.
Option D: Option D is incorrect. Dopamine agonists cannot reliably overcome D2 receptor blockade by a high-affinity antagonist such as olanzapine at clinical doses; attempting to compete at a blocked receptor with an agonist does not restore meaningful D2 signaling and risks worsening psychiatric symptoms through mesolimbic dopaminergic stimulation.
Option E: Option E is incorrect. Reducing olanzapine by 50% without substitution risks psychiatric relapse in a patient with a severe psychiatric history; the preferred approach is switching to a lower-D2-affinity agent that can maintain psychiatric efficacy while reducing motor adverse effects, rather than accepting inadequate antipsychotic coverage.

2. A 77-year-old man with advanced Parkinson's disease on levodopa/carbidopa five times daily is scheduled for elective right hemicolectomy. The surgical resident writes preoperative orders including "NPO after midnight — hold all oral medications." The patient's daughter, who is a pharmacist, raises concerns. The attending surgeon asks the neurology consultant what should be done differently. Which perioperative pharmacological plan is most appropriate?

A) Apply a rotigotine transdermal patch preoperatively to maintain dopaminergic tone through the nil-by-mouth period; ensure all antiparkinson medications are restarted at the earliest safe postoperative opportunity; explicitly communicate levodopa's one-hour half-life and the aspiration risk of acute akinesia to the entire perioperative team
B) Hold all antiparkinson medications as planned but administer intravenous dopamine at 3 mcg/kg/min during the surgical period to maintain peripheral dopaminergic tone while the patient is unable to take oral medications
C) Administer the morning levodopa dose by crushing it and mixing it with 100 mL of water given via nasogastric tube immediately before induction, then resume oral medications when bowel function returns postoperatively
D) Convert the patient to oral pramipexole extended-release the evening before surgery, as its longer duration of action provides a buffer through a brief NPO period without requiring transdermal delivery
E) Hold all medications as written and reassure the family that a single missed day of levodopa carries minimal risk in a patient whose disease has been well controlled for years

ANSWER: A

Rationale:

This question asked you to identify the correct perioperative pharmacological plan for a patient with advanced Parkinson's disease facing a nil-by-mouth period. Option A is correct across all components. Levodopa has a plasma half-life of approximately one hour, meaning therapeutic concentrations fall within hours of the last oral dose. In a patient with advanced PD whose motor function depends heavily on continuous dopaminergic support, this produces progressive akinesia, rigidity, and eventually severe dysphagia with aspiration risk — a life-threatening perioperative complication. Rotigotine transdermal is the established solution: it delivers continuous dopamine agonist activity through the skin without requiring gastrointestinal access and can be applied before surgery and maintained through the fasting period. Restarting oral antiparkinson medications at the earliest safe postoperative opportunity is equally essential. Explicit written communication of these imperatives to the entire perioperative team — surgeons, anesthesiologists, and nursing staff — is mandatory, as unfamiliarity with antiparkinson medication urgency is a common cause of preventable perioperative deterioration.

Option B: Option B is incorrect. Intravenous dopamine does not cross the blood-brain barrier and therefore provides no central antiparkinson benefit; peripheral dopamine infusion cannot substitute for central dopaminergic therapy and would not prevent akinesia or aspiration.
Option C: Option C is incorrect. Nasogastric tube levodopa administration is not the standard perioperative strategy and adds procedural risk; rotigotine transdermal is the established, less invasive solution for the NPO period. The nasogastric approach also depends on gastric motility, which may be impaired in the perioperative period.
Option D: Option D is incorrect. Oral pramipexole extended-release still requires gastrointestinal absorption and cannot be administered during a nil-by-mouth period; switching formulations the evening before surgery does not solve the problem of oral medication restriction during and after surgery.
Option E: Option E is incorrect. Holding all medications for a patient with advanced PD for even one day is dangerous — levodopa's short half-life means that clinically significant motor deterioration and aspiration risk emerge within hours, not days. A history of good disease control does not change the pharmacokinetic reality of levodopa's brief duration of action.

3. A 68-year-old man with Parkinson's disease on rasagiline 1 mg daily undergoes elective knee replacement. In the post-anesthesia care unit he receives meperidine 50 mg IV for pain. Twenty minutes later he develops a temperature of 39.8°C, severe generalized rigidity, diaphoresis, agitation, and a heart rate of 128 bpm. The PACU nurse calls for urgent assessment. Which action is most immediately appropriate, and which opioid can be safely used for ongoing pain management?

A) Administer dantrolene IV immediately for malignant hyperthermia, then transition to oral tramadol for ongoing analgesia once the acute episode resolves
B) Administer naloxone IV to reverse opioid toxicity, then use oral oxycodone with caution as an alternative analgesic given meperidine's unusual adverse effect profile in PD patients
C) Stop the meperidine infusion, administer cooling measures and supportive care for serotonin syndrome, then use oral tramadol for ongoing analgesia as it lacks the serotonergic properties of meperidine
D) Immediately discontinue the meperidine, provide supportive care for serotonin syndrome including cooling and benzodiazepines for agitation, and transition to morphine or oxycodone for ongoing analgesia as these opioids lack clinically significant serotonin reuptake inhibiting activity
E) Continue the meperidine at a reduced dose of 25 mg and administer cyproheptadine to block serotonin receptors, allowing continued opioid analgesia while managing the serotonergic adverse effect

ANSWER: D

Rationale:

This question asked you to recognize serotonin syndrome from the meperidine-rasagiline interaction, take immediate appropriate action, and identify a safe analgesic alternative. Option D is correct across all three clinical decisions. The presentation — fever, severe rigidity, diaphoresis, agitation, and tachycardia within minutes of meperidine administration in a patient on an MAO-B inhibitor — is a classic and life-threatening serotonin syndrome. Meperidine is unique among common opioid analgesics in possessing serotonin reuptake inhibiting properties; combined with rasagiline's MAO-B inhibition (which reduces serotonin catabolism), synaptic serotonin reaches toxic levels. The immediate action is discontinuation of meperidine — removing the precipitating serotonergic agent — followed by supportive care: cooling for hyperthermia, benzodiazepines for agitation and muscle hyperactivity (which also help with the rigidity), and hemodynamic monitoring. For ongoing analgesia, morphine and oxycodone are safe alternatives because they lack the serotonin reuptake inhibiting property that makes meperidine dangerous in the presence of MAO inhibitors; standard mu-opioid agonist activity without serotonergic activity does not produce this interaction.

Option A: Option A is incorrect. Dantrolene is the treatment for malignant hyperthermia, a condition caused by volatile anesthetic triggering of ryanodine receptor dysfunction in skeletal muscle; the clinical presentation here — with its rapid onset after meperidine, not after volatile anesthetic exposure — is pharmacologically attributable to serotonin syndrome, not malignant hyperthermia. Tramadol is contraindicated: it is a serotonin-norepinephrine reuptake inhibitor in addition to an opioid agonist and would perpetuate the serotonergic interaction with rasagiline.
Option B: Option B is incorrect. Naloxone reverses mu-opioid receptor-mediated effects but does not address serotonin syndrome, which is not an opioid toxicity syndrome; the clinical picture cannot be explained by meperidine's opioid activity alone, and naloxone would not resolve the hyperthermia, rigidity, or autonomic instability. Oxycodone is a reasonable alternative but requires no special caution specifically because of PD — it is simply a safe non-serotonergic opioid.
Option C: Option C is incorrect. Tramadol is explicitly contraindicated in combination with MAO-B inhibitors because tramadol itself is a serotonin and norepinephrine reuptake inhibitor; using tramadol as a "safe" alternative in a patient on rasagiline would risk precipitating an identical or worse serotonergic interaction.
Option E: Option E is incorrect. Continuing meperidine at a reduced dose perpetuates the interaction; cyproheptadine can be used as adjunctive therapy for serotonin syndrome to block postsynaptic 5-HT2A receptors, but it does not make it safe to continue administering a serotonin reuptake inhibitor alongside an MAO inhibitor — the source of excess serotonin must be removed first.

4. An 84-year-old woman with Parkinson's disease has fallen four times in three months. Her medications include levodopa/carbidopa, benztropine 1 mg twice daily for tremor, oxybutynin 5 mg twice daily for overactive bladder, and diphenhydramine 25 mg nightly for sleep. Her mini-mental state examination score has declined from 26 to 22 over the past year. Her daughter asks whether any medications could be contributing to her falls and cognitive decline. Which pharmacological intervention is most likely to reduce both fall risk and cognitive adverse effects in this patient?

A) Reduce the levodopa/carbidopa dose by 30% to decrease orthostatic hypotension, accepting some increase in motor symptoms as the trade-off for improved stability
B) Discontinue diphenhydramine, which has potent central anticholinergic activity producing sedation, impaired reaction time, and cognitive blunting that are particularly harmful in an older patient with already-reduced cholinergic reserve, and substitute with a safer sleep alternative such as melatonin
C) Switch oxybutynin to mirabegron, a beta-3 adrenergic agonist for overactive bladder that lacks anticholinergic activity, as the priority is reducing bladder-specific anticholinergic burden while preserving the other agents
D) Add rivastigmine to counteract the combined anticholinergic burden by enhancing cholinergic neurotransmission, which will also provide benefit for the concurrent cognitive decline
E) Discontinue benztropine and oxybutynin simultaneously, replacing both with a single low-dose anticholinergic agent to consolidate the anticholinergic burden into one drug that can be more easily monitored

ANSWER: B

Rationale:

This question asked you to identify which specific pharmacological intervention most effectively addresses the cumulative anticholinergic burden contributing to falls and cognitive decline in this older patient. Option B is correct. This patient is receiving three agents with significant anticholinergic activity — benztropine, oxybutynin, and diphenhydramine — and their combined anticholinergic burden substantially exceeds what any single agent would produce. Diphenhydramine is the highest-priority target for discontinuation: it is a first-generation antihistamine with potent central muscarinic receptor blocking activity, producing sedation, slowed reaction time, impaired working memory, and cognitive blunting that are severely amplified in older patients with reduced cholinergic reserve. It provides the weakest clinical justification of the three agents — insomnia in an older adult can be addressed with melatonin, low-dose doxepin, or sleep hygiene without any anticholinergic burden. Discontinuing diphenhydramine removes the most cognitively harmful agent while preserving the antiparkinson benefit of benztropine and the bladder benefit of oxybutynin, which can then be addressed in sequence.

Option A: Option A is incorrect. While levodopa does contribute to orthostatic hypotension and therefore falls, reducing the levodopa dose to address fall risk risks worsening motor symptoms and dysphagia — a potentially more dangerous trade-off in a patient with advanced age and already-compromised motor function. The anticholinergic burden is a more addressable immediate target.
Option C: Option C is incorrect. Switching oxybutynin to mirabegron is an appropriate strategy to reduce bladder-specific anticholinergic burden and should be part of the overall deprescribing plan; however, it is not the single most impactful intervention because oxybutynin, while anticholinergic, has less central CNS penetration than diphenhydramine. Diphenhydramine's central anticholinergic activity is more immediately harmful to cognition and reaction time.
Option D: Option D is incorrect. Adding rivastigmine to compensate for anticholinergic burden through cholinesterase inhibition is pharmacologically inappropriate before removing the anticholinergic agents causing the problem; adding a cholinomimetic while continuing three anticholinergic drugs forces two opposing pharmacological mechanisms to compete, and rivastigmine itself carries adverse effects including nausea and dizziness that increase fall risk.
Option E: Option E is incorrect. Discontinuing both benztropine and oxybutynin simultaneously while substituting a single lower-dose anticholinergic would worsen tremor and bladder symptoms and still leaves anticholinergic burden in the regimen; the correct approach is to remove the agent with the least clinical justification first — diphenhydramine — rather than consolidating burden.

5. A 35-year-old woman with young-onset Parkinson's disease is referred urgently to a movement disorder specialist after a home pregnancy test confirms she is approximately eight weeks pregnant. Her current regimen is levodopa/carbidopa 25/100 mg four times daily, ropinirole 4 mg three times daily, and selegiline 5 mg twice daily. She asks which of her medications she should take today while she waits for her appointment. Which immediate recommendation is most consistent with the evidence-based hierarchy of antiparkinson drug safety in pregnancy?

A) Stop all three medications immediately until she can be seen by her movement disorder specialist, as no antiparkinson drug is considered safe in the first trimester and the risk of fetal exposure during organogenesis outweighs the risk of untreated motor symptoms for one to two weeks
B) Continue all three medications unchanged until specialist review, as abrupt discontinuation of any of these agents carries risks that outweigh the theoretical fetal concerns during a brief pre-appointment period
C) Stop ropinirole immediately and reduce selegiline to once daily, but continue levodopa/carbidopa unchanged, as MAO-B inhibitors are the highest-risk class in pregnancy and dopamine agonists require dose reduction rather than full discontinuation
D) Continue levodopa/carbidopa and ropinirole unchanged but stop selegiline, as MAO-B inhibitors are the highest-risk class in pregnancy while non-ergot dopamine agonists have an established safety record in the first trimester
E) Continue levodopa/carbidopa at the current or lowest effective dose as the safest available agent with the most human pregnancy data; discontinue ropinirole and selegiline, as dopamine agonists and MAO-B inhibitors lack adequate human pregnancy safety data and should be stopped pending specialist review

ANSWER: E

Rationale:

This question asked you to apply the evidence-based hierarchy of antiparkinson drug safety in pregnancy to provide immediate guidance before specialist review. Option E is correct and reflects the correct risk stratification across all three agents. Levodopa/carbidopa is continued at the current or lowest effective dose: it has the longest and most substantial human pregnancy experience of any antiparkinson drug, case series have not demonstrated a consistent teratogenic signal at therapeutic doses, and the risks of untreated motor disability — including falls, aspiration, and functional impairment — are genuine concerns during pregnancy. Ropinirole is discontinued: non-ergot dopamine agonists have very limited human pregnancy data, are classified based on preclinical toxicology findings, and are generally avoided during the first trimester when organogenesis is occurring. Selegiline is discontinued: MAO-B inhibitors have essentially no human pregnancy safety data, carry theoretical risks from effects on monoamine metabolism during fetal development, and should be stopped when an alternative exists. This three-tier hierarchy — levodopa safe to continue, agonists and MAO-B inhibitors discontinued — is the established clinical approach.

Option A: Option A is incorrect. Stopping levodopa entirely in a patient with established symptomatic PD is inappropriate and potentially dangerous during pregnancy; levodopa is the safest available antiparkinson agent and should be continued when motor symptoms require treatment.
Option B: Option B is incorrect. Continuing ropinirole and selegiline unchanged ignores the meaningful difference in pregnancy safety profiles between levodopa and the other two agents; the risk-benefit calculation clearly favors discontinuing the agents with the least pregnancy data before specialist review.
Option C: Option C is incorrect. Reducing selegiline to once daily rather than discontinuing it does not address the absence of safety data; the appropriate action is discontinuation, not dose reduction. Additionally, ropinirole requires discontinuation rather than dose reduction given the limited first-trimester safety data.
Option D: Option D is incorrect. The claim that non-ergot dopamine agonists have an established safety record in the first trimester is not accurate; ropinirole has very limited human pregnancy data and is not considered established as safe in the first trimester. The hierarchy places levodopa above agonists, not agonists above MAO-B inhibitors.

6. A 56-year-old woman with a ten-year history of epilepsy has been on valproic acid 1000 mg twice daily for seven years with excellent seizure control. She presents to neurology with a five-month history of bilateral bradykinesia, mild rigidity, and slowed gait. She has no family history of Parkinson's disease and has never taken antipsychotics or antiemetics. DAT-SPECT imaging shows normal dopamine transporter binding bilaterally. Her epileptologist considers reducing her valproic acid dose. Which statement best guides the clinical decision and sets realistic expectations for recovery?

A) The normal DAT scan excludes valproic acid as the cause because drugs capable of producing true parkinsonism must reduce DAT binding; she requires a full evaluation for idiopathic Parkinson's disease or an atypical parkinsonian syndrome
B) The normal DAT scan confirms valproic acid-induced parkinsonism through D2 receptor blockade; dose reduction will restore full motor function within two to four weeks as receptor occupancy falls with plasma drug levels
C) The normal DAT scan is consistent with valproic acid-induced parkinsonism but also with early idiopathic PD; dose reduction should not be attempted as disrupting seizure control poses greater risk than managing the motor symptoms pharmacologically with levodopa addition
D) The normal DAT scan is consistent with valproic acid-induced parkinsonism through a mitochondrial dysfunction mechanism that preserves structural neuronal integrity; dose reduction is appropriate and may improve motor symptoms, though complete resolution cannot be guaranteed if subclinical idiopathic PD has been unmasked
E) The normal DAT scan confirms pure drug-induced parkinsonism with no neurodegeneration; full valproic acid discontinuation is required for complete motor recovery, and her seizures should be managed with a non-valproate antiepileptic during the transition period

ANSWER: D

Rationale:

This question asked you to interpret the DAT scan result in the context of valproic acid use and set realistic clinical expectations for treatment response. Option D is correct. Valproic acid produces parkinsonism through mitochondrial dysfunction in dopaminergic neurons — impairing their metabolic function and dopamine neurotransmission capacity — without causing the structural loss of presynaptic terminals that would reduce DAT binding. A normal DAT scan is therefore the expected finding in valproic acid-induced parkinsonism and directly confirms that nigrostriatal dopaminergic terminals are structurally present. Reducing the valproic acid dose is appropriate: mitochondrial dysfunction is concentration-dependent and partially reversible, so lower drug exposure may improve neuronal metabolic function and motor symptoms. However, complete resolution cannot be guaranteed for two reasons: first, mitochondrial recovery may be incomplete; second, valproic acid exposure may have pharmacologically stressed an already-reduced dopaminergic reserve, unmasking subclinical idiopathic Parkinson's disease that will continue to progress independently. Dose reduction rather than full discontinuation is the appropriate initial step, preserving seizure control while testing the reversibility of the motor symptoms.

Option A: Option A is incorrect. A normal DAT scan does not exclude drug-induced parkinsonism — it is precisely the expected finding in DIP from agents that produce functional neuronal impairment without structural terminal loss, of which valproic acid is the prototypical example. Requiring DAT reduction as a criterion for drug-induced parkinsonism is pharmacologically incorrect.
Option B: Option B is incorrect. Valproic acid does not cause parkinsonism through D2 receptor blockade — that is the mechanism of antipsychotic-induced DIP. Valproate's mechanism is mitochondrial dysfunction, not receptor occupancy, and the time course and completeness of recovery will differ accordingly; two to four weeks for full recovery after mere dose reduction is unrealistically optimistic.
Option C: Option C is incorrect. The clinical scenario calls for dose reduction as the first management step, not for pharmacological bypassing of the cause with levodopa addition; levodopa would be appropriate if dose reduction fails and the symptoms are severe enough to warrant it, but it is not the first-line response to suspected drug-induced parkinsonism when the causative agent can be adjusted.
Option E: Option E is incorrect. Full discontinuation of valproic acid in a patient with excellent seizure control on a long-established regimen is a disproportionate initial response; dose reduction tests the motor response while maintaining seizure control, and the assertion that full discontinuation is required for complete recovery presumes greater certainty about prognosis than the clinical evidence warrants.

7. A 79-year-old man with Parkinson's disease on levodopa/carbidopa is on postoperative day two following elective hip replacement. He becomes acutely agitated and confused overnight, pulling at his IV lines and calling out. The on-call hospitalist reviews the standard delirium protocol and is about to order haloperidol 1 mg IV. The night pharmacist intercepts the order. Which explanation and alternative order is most appropriate?

A) Haloperidol must not be used in this patient because it is a high-affinity D2 receptor antagonist that will directly oppose the dopaminergic therapy maintaining his motor function, causing severe rigidity, worsening bradykinesia, and potentially life-threatening dysphagia; substitute quetiapine 12.5 mg orally or, if oral administration is not possible, hold pharmacological management and optimize non-pharmacological delirium measures while reassessing antiparkinson medication continuity
B) Haloperidol must not be used because it prolongs the QTc interval specifically in patients on levodopa due to a pharmacokinetic interaction that elevates both drug levels; substitute lorazepam 0.5 mg IV, which is safe in PD and equally effective for acute agitation in the elderly
C) Haloperidol must not be used because it inhibits CYP1A2, reducing levodopa metabolism and causing levodopa accumulation that will worsen psychotic symptoms through excess dopaminergic stimulation; substitute olanzapine 2.5 mg, which does not affect CYP enzymes
D) Haloperidol must not be used because its anticholinergic properties will compound the cholinergic deficit of Parkinson's disease, worsening cognitive function; substitute diphenhydramine 25 mg, which provides sedation without anticholinergic striatal effects
E) Haloperidol can be used at a reduced dose of 0.25 mg IV in this patient as the benefits of rapid agitation control outweigh the small risk of motor worsening at sub-therapeutic antipsychotic doses; add benztropine prophylactically to prevent extrapyramidal adverse effects

ANSWER: A

Rationale:

This question asked you to identify the correct pharmacological reasoning for haloperidol's contraindication in Parkinson's disease and provide an appropriate clinical alternative. Option A is correct in both the explanation and the recommendation. Haloperidol is a first-generation antipsychotic with very high D2 receptor affinity. In a patient with Parkinson's disease, striatal D2 receptor activation by endogenous dopamine — supplemented by levodopa therapy — is the pharmacological basis for maintaining motor function. Blocking these D2 receptors with haloperidol directly antagonizes this therapeutic effect, producing severe motor deterioration: markedly increased rigidity, worsening bradykinesia, impaired swallowing, and potentially fatal aspiration. This is not a dose-dependent concern that can be managed by dose reduction — even low doses of haloperidol can cause clinically significant motor worsening in PD, and there is no safe dose. Quetiapine at 12.5 to 25 mg is the appropriate pharmacological alternative because its very low D2 receptor affinity at these doses avoids meaningful striatal D2 blockade. If oral administration is not feasible, optimizing non-pharmacological delirium measures — reorientation, appropriate lighting, family presence, normalization of sleep-wake cycle — and ensuring antiparkinson medications have been restarted are the highest-priority interventions.

Option B: Option B is incorrect. While haloperidol does prolong QTc, QTc prolongation is not the primary or defining contraindication in PD; the D2 receptor-mediated motor deterioration is the critical concern. Lorazepam is not equivalent to haloperidol for delirium management and carries its own significant risks in elderly patients — paradoxical agitation, respiratory depression, and falls — making it a poor default substitute.
Option C: Option C is incorrect. Haloperidol does not meaningfully inhibit CYP1A2, and levodopa is not significantly metabolized by CYP enzymes in a way that creates this interaction; the contraindication is pharmacodynamic through D2 receptor blockade, not pharmacokinetic. Olanzapine has significant D2 receptor affinity and is not an appropriate substitute in PD.
Option D: Option D is incorrect. Haloperidol is not primarily an anticholinergic agent — it is a D2 receptor antagonist. The core contraindication is dopaminergic, not cholinergic. Diphenhydramine is a first-generation antihistamine with potent central anticholinergic activity that would worsen cognitive function and delirium in an older PD patient — the opposite of therapeutic.
Option E: Option E is incorrect. There is no evidence-supported safe dose of haloperidol in Parkinson's disease; the claim that 0.25 mg carries only a small risk of motor worsening is not supported by clinical pharmacology or practice guidelines. Adding benztropine does not prevent D2-mediated motor deterioration and would add anticholinergic burden in an already-delirious elderly patient.

8. A 64-year-old woman with Parkinson's disease was started on tolcapone six weeks ago for wearing-off management after failing entacapone due to diarrhea. She presents for her scheduled follow-up. She feels her motor control has improved substantially. Routine laboratory tests show her alanine aminotransferase (ALT) is 3.2 times the upper limit of normal; it was normal at baseline six weeks ago. She has no jaundice, abdominal pain, or fatigue. Which action is most appropriate?

A) Continue tolcapone at the current dose and repeat liver function tests in eight weeks, as mild transaminase elevations are expected with tolcapone and resolve spontaneously without dose adjustment in the majority of patients
B) Reduce the tolcapone dose by 50% and repeat liver function tests in two weeks, as dose-dependent hepatotoxicity from tolcapone can be managed with dose reduction rather than discontinuation in the early stages
C) Discontinue tolcapone immediately given the significant ALT elevation in the context of its black-box hepatotoxicity warning; arrange urgent hepatology review, counsel the patient on symptoms of hepatic decompensation to watch for, and discuss alternative wearing-off management options such as adding a MAO-B inhibitor or adjusting the levodopa dosing interval
D) Continue tolcapone and add ursodeoxycholic acid to provide hepatoprotection, as the motor benefit is substantial and mild transaminase elevation is a manageable adverse effect that does not require drug discontinuation in asymptomatic patients
E) Switch from tolcapone to entacapone despite the prior diarrhea, as entacapone does not carry hepatotoxicity risk and the patient's diarrhea may resolve with a lower starting dose; the ALT elevation on tolcapone requires management but not urgent drug discontinuation

ANSWER: C

Rationale:

This question asked you to respond appropriately to a significant ALT elevation in a patient on tolcapone. Option C is correct. Tolcapone carries a black-box warning for potentially fatal hepatotoxicity, including cases of fulminant hepatic failure resulting in death. The mandatory monitoring program — baseline liver function tests followed by periodic testing during therapy — exists precisely to detect early hepatotoxicity before it progresses to irreversible liver injury. An ALT elevation of 3.2 times the upper limit of normal at six weeks, in an asymptomatic patient with a previously normal baseline, is a clinically significant signal that requires immediate drug discontinuation. The absence of jaundice, abdominal pain, or fatigue does not make this finding benign — fulminant hepatic failure can develop rapidly from a point of asymptomatic transaminase elevation, and the time to act is before symptoms appear. Discontinuing tolcapone, arranging hepatology review, monitoring for hepatic decompensation symptoms, and planning alternative wearing-off management are all appropriate concurrent steps. Patients lost to this monitoring and follow-up process are at greatest risk of progressing to severe liver injury.

Option A: Option A is incorrect. Mild asymptomatic transaminase elevations are not an expected and benign feature of tolcapone therapy to be observed and repeated at leisure; any significant elevation above baseline in a patient on tolcapone represents a hepatotoxicity signal that requires discontinuation, not watchful waiting.
Option B: Option B is incorrect. Dose reduction is not an established management strategy for tolcapone-induced hepatotoxicity; the prescribing information and clinical guidelines recommend discontinuation when liver enzyme elevations occur, not dose titration downward.
Option D: Option D is incorrect. Ursodeoxycholic acid is used for certain cholestatic liver conditions but is not an established hepatoprotective agent for drug-induced hepatotoxicity from tolcapone; continuing tolcapone and adding hepatoprotection is not an evidence-based approach and ignores the black-box warning mandate to discontinue when significant liver enzyme elevations occur.
Option E: Option E is incorrect. Switching to entacapone is a reasonable long-term plan for managing wearing-off without hepatotoxicity risk, and entacapone at a lower dose may be better tolerated for the prior diarrhea; however, the phrasing that the ALT elevation "does not require urgent drug discontinuation" contradicts the clinical imperative established by tolcapone's black-box warning — discontinuation upon significant liver enzyme elevation is urgent, not deferred.

9. A 61-year-old man with Parkinson's disease has been on pramipexole 1.5 mg three times daily for four years. After reading an online article about dopamine agonist-induced gambling addiction, he stopped pramipexole abruptly five days ago without informing his neurologist. He now presents to the emergency department with severe anxiety, profuse sweating, dysphoria, insomnia, and an intense urge to take pramipexole. His motor symptoms are modestly worsened but he rates the non-motor symptoms as far more distressing. He denies any history of impulse control disorder. Which diagnosis and management plan is most appropriate?

A) Acute levodopa toxicity from unopposed dopaminergic stimulation after pramipexole removal; reduce his levodopa dose by 25% and provide benzodiazepine anxiolysis while the dopaminergic system rebalances over 48 to 72 hours
B) Dopamine agonist withdrawal syndrome from abrupt pramipexole discontinuation; reinstate pramipexole at the previous dose to resolve the acute withdrawal state, then arrange a structured slow taper over weeks to months with appropriate counseling about the risks and management of impulse control disorder
C) Serotonin discontinuation syndrome from pramipexole's activity at 5-HT1A receptors; administer fluoxetine to stabilize serotonergic tone and gradually taper pramipexole over the following four weeks under medical supervision
D) Noradrenergic withdrawal syndrome from loss of pramipexole's inhibitory effect on locus coeruleus firing; administer clonidine 0.1 mg twice daily to suppress adrenergic discharge and taper over two weeks while transitioning to levodopa monotherapy
E) Acute psychiatric decompensation from mesolimbic dopamine receptor hypersensitivity after sudden agonist removal; admit for inpatient psychiatric observation and administer quetiapine 25 mg twice daily to stabilize mesolimbic dopaminergic tone

ANSWER: B

Rationale:

This question asked you to correctly diagnose dopamine agonist withdrawal syndrome and prescribe appropriate management. Option B is correct. The clinical picture is characteristic of dopamine agonist withdrawal syndrome (DAWS): severe non-motor symptoms — anxiety, dysphoria, diaphoresis, insomnia, and drug craving — emerging within days of abrupt discontinuation of a dopamine agonist after years of chronic use, with the non-motor symptoms disproportionately distressing relative to motor worsening. DAWS reflects physical dependence of the mesolimbic reward system on chronic dopaminergic agonist stimulation; abrupt removal produces a withdrawal state pharmacologically analogous in some respects to substance withdrawal. The correct management has two components: first, reinstatement of pramipexole at the previously tolerated dose to resolve the acute withdrawal state — tapering from zero is not effective when full withdrawal syndrome has already developed; second, a planned gradual taper over weeks to months with appropriate counseling. Regarding the impulse control disorder concern: the correct response is a structured supervised taper with behavioral monitoring, not abrupt self-discontinuation, which this patient has now learned firsthand produces its own serious adverse consequences.

Option A: Option A is incorrect. The non-motor symptoms of DAWS are not attributable to levodopa toxicity; levodopa excess produces dyskinesia, nausea, and psychosis, not anxiety, drug craving, and diaphoresis. Reducing levodopa will worsen motor function without addressing the mesolimbic withdrawal state.
Option C: Option C is incorrect. While pramipexole has some 5-HT1A receptor activity, the withdrawal syndrome it produces is not a serotonin discontinuation syndrome and is not treated with fluoxetine; the established mechanism is mesolimbic dopamine D2/D3 receptor dependence.
Option D: Option D is incorrect. DAWS is not a noradrenergic withdrawal syndrome; while autonomic symptoms (sweating, anxiety) superficially resemble adrenergic withdrawal, the pharmacological mechanism is mesolimbic dopaminergic, not noradrenergic. Clonidine addresses adrenergic symptoms only and does not treat the root cause.
Option E: Option E is incorrect. The presentation is not acute psychiatric decompensation or mesolimbic receptor hypersensitivity; quetiapine would further reduce mesolimbic dopaminergic tone and could worsen the withdrawal state. DAWS is treated by restoring the dopaminergic agonist, not by adding antidopaminergic agents.

10. A 73-year-old woman with Parkinson's disease on levodopa/carbidopa 25/100 mg four times daily reports excellent motor function in the morning but consistent "freezing" and wearing-off beginning approximately 90 minutes after her midday meal. Her husband notes that she typically eats a substantial lunch including meat, dairy, and legumes. Levodopa dose and timing adjustments have not resolved the problem. Which intervention addresses the underlying pharmacokinetic mechanism most directly, and what is the correct explanation to give this patient?

A) Add entacapone to each levodopa dose to extend the plasma half-life of levodopa beyond the period of amino acid competition; the protein in her lunch elevates gastric pH, reducing levodopa dissolution, and entacapone corrects this by slowing gastric emptying
B) Switch to controlled-release levodopa/carbidopa, which releases drug slowly over four to six hours and bypasses the absorptive window during which dietary amino acids are at their peak plasma concentration after a protein-rich meal
C) Reduce protein intake uniformly across all three meals to a low-protein diet throughout the day, eliminating the LNAA competitive load at all times and providing consistent levodopa absorption regardless of meal composition
D) Take each levodopa dose with a large glass of orange juice to acidify the gastric environment and improve tablet dissolution, offsetting the pH-raising effect of dietary protein on levodopa bioavailability
E) Redistribute dietary protein so that most of the day's protein is consumed at the evening meal while keeping breakfast and lunch low in protein; dietary amino acids compete with levodopa for the large neutral amino acid transporter at both the intestinal epithelium and the blood-brain barrier, and removing this competitive load during the active daytime period will restore afternoon levodopa efficacy

ANSWER: E

Rationale:

This question asked you to select the intervention that directly addresses the pharmacokinetic mechanism of meal-related levodopa wearing-off and provide the correct patient explanation. Option E is correct. The mechanism is large neutral amino acid (LNAA) transporter competition at two anatomical sites. Levodopa relies on the LNAA transporter for absorption across the intestinal epithelium into systemic circulation and for transport across the blood-brain barrier into the CNS. After a high-protein meal, digestion releases a large bolus of dietary amino acids — phenylalanine, tyrosine, leucine, isoleucine, valine, and others — that compete with levodopa for these transporters at both sites simultaneously. This reduces both intestinal absorption and CNS delivery of levodopa, producing the characteristic post-meal wearing-off. The protein redistribution diet concentrates the day's protein in the evening meal when the need for reliable motor function is least critical, removing the competitive amino acid load from both transport sites during the daytime period when the patient most needs consistent levodopa efficacy. This explanation can be given directly to the patient in accessible terms: "The protein in your lunch is competing with your levodopa for the same doorway into your bloodstream and into your brain. If we move most of your protein to dinner, your midday levodopa can get through more reliably."

Option A: Option A is incorrect. Entacapone inhibits peripheral COMT-mediated levodopa degradation, extending plasma levodopa half-life — a useful adjunct for wearing-off in general — but it does not address LNAA transporter competition, which is the specific mechanism of meal-related wearing-off. Entacapone does not slow gastric emptying, and dietary protein does not raise gastric pH in a way relevant to levodopa absorption.
Option B: Option B is incorrect. Controlled-release levodopa/carbidopa releases drug slowly but still depends on the same LNAA transporter for intestinal absorption; the competitive amino acid load from protein digestion affects controlled-release formulations as it does immediate-release, and switching formulations alone does not resolve protein-related wearing-off.
Option C: Option C is incorrect. A uniformly low-protein diet throughout the day is nutritionally unsafe and unnecessary; the protein redistribution strategy achieves the clinical goal — protecting daytime levodopa efficacy — without restricting protein intake overall, by concentrating it in the evening rather than eliminating it.
Option D: Option D is incorrect. Orange juice does not meaningfully acidify the stomach in a way that improves levodopa tablet dissolution, and dietary protein does not raise gastric pH sufficiently to impair dissolution as a primary mechanism of wearing-off; the LNAA transporter competition mechanism, not pH-dependent dissolution, is responsible for this patient's postprandial motor deterioration.

11. A 70-year-old man with Parkinson's disease on rasagiline 1 mg daily, levodopa/carbidopa, and entacapone presents with dysuria and frequency. Urine culture grows Escherichia coli sensitive to ciprofloxacin, trimethoprim-sulfamethoxazole, and nitrofurantoin. His primary care physician calls to ask whether ciprofloxacin is safe given his antiparkinson regimen. Which response and recommendation is most pharmacologically appropriate?

A) Ciprofloxacin is safe with this regimen; the only antiparkinson drug interaction concern with fluoroquinolones is with entacapone, which ciprofloxacin inhibits through a COMT-enzyme competition mechanism that can be managed by temporarily halving the entacapone dose
B) Ciprofloxacin is safe with this regimen; rasagiline drug interactions are limited to serotonergic agents and sympathomimetics, and ciprofloxacin does not fall into either category
C) Ciprofloxacin is contraindicated with rasagiline due to a pharmacodynamic interaction at MAO-B binding sites that reverses rasagiline's neuroprotective effect; substitute trimethoprim-sulfamethoxazole, which has no antiparkinson interactions
D) Ciprofloxacin should be avoided in this patient because it is a potent CYP1A2 inhibitor; rasagiline is metabolized primarily by CYP1A2, and co-administration will substantially reduce rasagiline clearance, elevating its plasma concentrations and increasing the risk of rasagiline-associated drug interactions including serotonin syndrome with any serotonergic co-medications; trimethoprim-sulfamethoxazole or nitrofurantoin are safer alternatives for this infection
E) Ciprofloxacin is safe if the rasagiline dose is halved to 0.5 mg daily for the duration of the antibiotic course, as dose reduction compensates for the reduced hepatic clearance caused by CYP1A2 inhibition and restores rasagiline to its intended therapeutic plasma concentration

ANSWER: D

Rationale:

This question asked you to identify the clinically significant drug interaction between ciprofloxacin and rasagiline and recommend an appropriate antibiotic alternative. Option D is correct. Rasagiline is metabolized in the liver primarily by CYP1A2 via N-dealkylation to its principal metabolite aminoindan. Ciprofloxacin is a potent inhibitor of CYP1A2, one of the most clinically important drug-metabolizing enzymes. Co-administration reduces rasagiline's hepatic clearance substantially, elevating plasma rasagiline concentrations well above the intended therapeutic range. At elevated concentrations, the risk of rasagiline's known dangerous drug interactions increases proportionally — most critically, the risk of serotonin syndrome in the event of exposure to meperidine, tramadol, or serotonergic antidepressants, and the risk of hypertensive reactions with sympathomimetic agents. This interaction is documented in rasagiline's prescribing information. Because this patient's urinary tract infection is sensitive to trimethoprim-sulfamethoxazole and nitrofurantoin — both of which do not meaningfully inhibit CYP1A2 — ciprofloxacin can and should be avoided. Either alternative provides effective treatment without the pharmacokinetic interaction.

Option A: Option A is incorrect. Ciprofloxacin does not interact with entacapone through a COMT-enzyme competition mechanism; entacapone is a COMT inhibitor and ciprofloxacin has no COMT-related pharmacology. The clinically significant interaction in this regimen is between ciprofloxacin and rasagiline via CYP1A2 inhibition.
Option B: Option B is incorrect. Rasagiline's drug interactions are not limited to serotonergic agents and sympathomimetics at the pharmacodynamic level; its pharmacokinetic interactions through CYP1A2 are equally clinically important, and ciprofloxacin as a CYP1A2 inhibitor directly falls within this category.
Option C: Option C is incorrect. Ciprofloxacin does not interact with rasagiline pharmacodynamically at MAO-B binding sites and does not reverse rasagiline's effect at the enzyme level; the interaction is entirely pharmacokinetic through CYP1A2 inhibition. Trimethoprim-sulfamethoxazole is a reasonable alternative for this infection, but the stated mechanism is incorrect.
Option E: Option E is incorrect. Empirically halving the rasagiline dose to compensate for CYP1A2 inhibition is an unvalidated approach; the magnitude of CYP1A2 inhibition by ciprofloxacin varies between patients and cannot be reliably predicted to be corrected by a 50% dose reduction. When a safe and effective antibiotic alternative is available — which it is in this case — avoiding the interacting agent entirely is the correct clinical decision rather than attempting dose adjustment of the substrate.